GlassScriptPhysician profile
Rina C Davis
NPI 1770578494
$8,619.99
in general payments reported to CMS, 2019-2025
27 companies · $242 in 2025
The $242 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,291 · 2020: $748 · 2021: $154 · 2022: $501 · 2023: $318 · 2024: $367 · 2025: $242.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $927.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $926.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mdd US Operations, LLC | $5,615.29 | 2019-2020 | |
| Allergan, INC. | $546.02 | 2019-2020 | |
| Abbvie INC. | $494.75 | 2021-2025 | Ubrelvy, Qulipta |
| Teva Pharmaceuticals USA, INC. | $391.68 | 2019-2024 | Ajovy |
| Pfizer INC. | $257.71 | 2021-2025 | |
| Collegium Pharmaceutical, INC. | $222.57 | 2019-2025 | Xtampza |
| Medtronic, INC. | $170.74 | 2022 | |
| Arbor Pharmaceuticals, INC. | $133.89 | 2019-2020 | |
| Amgen INC. | $127.53 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $105.33 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $88.29 | 2021 | |
| Lundbeck LLC | $78.45 | 2024-2025 | Vyepti |
| International Rehabilitative Sciences, INC | $56.10 | 2023-2024 | Rs 4i Plus Sequential Stimulator |
| Scilex Pharmaceuticals INC. | $47.70 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $45.65 | 2024 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $38.03 | 2023 | Keveyis, Gvoke Hypopen |
| Ibsa Pharma INC. | $32.39 | 2024-2025 | Tirosint, Licart, Flector |
| Nevro Corp. | $25.88 | 2019 | |
| Fidia Pharma USA INC. | $25.12 | 2019-2022 | |
| Tersera Therapeutics LLC | $23.34 | 2019 | |
| Daiichi Sankyo INC. | $19.56 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $13.89 | 2019 | |
| Novartis Pharmaceuticals Corporation | $13.38 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.30 | 2019 | |
| Spr Therapeutics, INC | $11.66 | 2023 | Sprint Pns System |
| Lilly USA, LLC | $11.53 | 2020 | |
| Si-Bone, INC. | $11.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rina Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.